MIRANDA VANCIL: Open Payments
NPI 1932637725 · ANDOVER, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,482 in 81 payments from 22 companies in 2025. Trend: 2023 $1,217 · 2024 $1,493 · 2025 $1,482
Food & beverage: $1,482
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $164 |
| Lilly USA, LLC | 9 | $162 |
| GlaxoSmithKline, LLC. | 7 | $161 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $156 |
| ABBVIE INC. | 12 | $153 |
| Astellas Pharma US Inc | 6 | $126 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $107 |
| Sumitomo Pharma America, Inc. | 4 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Amgen Inc. | 3 | $49 |
Products named: XIFAXAN, BREZTRI, TRELEGY ELLIPTA, Veozah, Kerendia, MOUNJARO, QULIPTA, UBRELVY.
Industry payments across KS — which companies pay providers there.
